Comparison of Mitoxantrone versus Cyclophosphamide Treatment in Patients with Secondary Progressive Multiple Sclerosis

Tuncay GÜNDÜZ; Gonca ÖZCAN; Arman ÇAKAR; Halil İbrahim AKÇAY; Ayşe Nur ÖZDAĞ ACARLI; Mefküre ERAKSOY; Murat KÜRTÜNCÜ

doi:https://doi.org/10.5798/dicletip.1086113

Makale detayları

Comparison of Mitoxantrone versus Cyclophosphamide Treatment in Patients with Secondary Progressive Multiple Sclerosis

Yazarlar:

Tuncay GÜNDÜZ | Gonca ÖZCAN | Arman ÇAKAR | Halil İbrahim AKÇAY | Ayşe Nur ÖZDAĞ ACARLI | Mefküre ERAKSOY | Murat KÜRTÜNCÜ

Yayıncı:

Dicle University

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Dicle Medical Journal 2022 Vol.49 Issue 1, pp.29-35

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000945951

Sıklık:

Üç Aylık

eISSN:

1308-9889

pISSN:

1300-2945

DOI:

https://doi.org/10.5798/dicletip.1086113

Özet:

 

Objective: Mitoxantrone (Mtx) and cyclophosphamide (Cyc) have successfully been used in highly aggressive multiple sclerosis (MS) patients. This study aims to compare the efficacy of these drugs in patients with secondary progressive MS (pwSPMS).
Method: Clinical data of pwSPMS treated with either Mtx or Cyc were collected retrospectively. The EDSS scores before, during, and after the drug was determined. The efficacy of the drug was evaluated according to the EDSS change after the completion of therapy. The variations in clinical benefit between the two groups were investigated, as well as the factors that influenced them.
Results: Fifty-nine SPMS patients (29 Mtx, 30 Cyc) were included in our study. Mean treatment periods were 19.5±9.9 months for Mtx and 9.1±4.1 months for the Cyc group. Mean EDSS in Mtx and Cyc groups at the first dose were 6.2±0.7 and 6.3±0.8, respectively (p=0.42). The percentage of patients who benefited from treatment was 41.6% in the Mtx group and 43.0% in the Cyc group (p=0.54). However, Mtx was more effective in patients with younger age of disease onset (p=0.01).
Conclusion: Immunosuppression with intravenous Mtx and Cyc may equally prevent progression in patients with SPMS. Additionally, Mtx may be more beneficial in MS patients with earlier disease onset.

Makale detayları

Comparison of Mitoxantrone versus Cyclophosphamide Treatment in Patients with Secondary Progressive Multiple Sclerosis

Yazarlar: Tuncay GÜNDÜZ | Gonca ÖZCAN | Arman ÇAKAR | Halil İbrahim AKÇAY | Ayşe Nur ÖZDAĞ ACARLI | Mefküre ERAKSOY | Murat KÜRTÜNCÜ

Yayıncı: Dicle University

Ana Başlıklar: Sağlık teşvikleri

Dergi: Dicle Medical Journal 2022 Vol.49 Issue 1, pp.29-35

Belge Tipi: Makale

Yayın Tarihi: 3/2022

Belge Dili: İngilizce

Document ID (Org No.): 2000945951

Sıklık: Üç Aylık

eISSN: 1308-9889

pISSN: 1300-2945

DOI: https://doi.org/10.5798/dicletip.1086113

Sayı

Yazarlar:

Tuncay GÜNDÜZ | Gonca ÖZCAN | Arman ÇAKAR | Halil İbrahim AKÇAY | Ayşe Nur ÖZDAĞ ACARLI | Mefküre ERAKSOY | Murat KÜRTÜNCÜ

Yayıncı:

Dicle University

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Dicle Medical Journal 2022 Vol.49 Issue 1, pp.29-35

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000945951

Sıklık:

Üç Aylık

eISSN:

1308-9889

pISSN:

1300-2945

DOI:

https://doi.org/10.5798/dicletip.1086113